Insulin degludec–liraglutide

A combination of ultra-long-acting insulin degludec and the GLP-1 receptor agonist liraglutide, FDA-approved for type 2 diabetes with diet and exercise.

psilodex.org/m/insulin-degludec-liraglutide · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~25 h; Approximate, in adults. Source under Interaction below.Effect duration: Insulin degludec component: glucose-lowering effect lasts at least 42 hours after the last dose

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Insulin degludec–liraglutide”, v2026.10.05. psilodex.org/m/insulin-degludec-liraglutide

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Sources [1]

FDA-approved for

Type 2 diabetes (with diet and exercise)

Sources [1]

Other safety

Boxed warning: liraglutide causes thyroid C-cell tumors in rats and mice, and it is unknown whether it does in humans. It is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

It may slow psilocybin absorption and add nausea, and its insulin can lower blood sugar. Stopping or pausing it can raise blood sugar.

Detail Liraglutide delays gastric emptying, which may slow absorption of oral psilocybin and add to nausea. The insulin degludec component can cause low blood sugar, especially with a light or skipped meal. Its glucose-lowering effect lasts at least 42 hours. The pen is also the person's basal insulin, so stopping or pausing it can raise blood sugar. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Effect duration: Insulin degludec component: glucose-lowering effect lasts at least 42 hours after the last dose Measured for insulin degludec alone (Tresiba label); Xultophy's label describes a duration reflecting both components. Sources [2]
Half-life: Insulin degludec ~25 h; liraglutide ~13 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

5 listed · counted on reports

Dehydration or electrolyte risk: Can cause dehydration or shifts in sodium or potassium. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Hypoglycemia risk: Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Slows gastric emptying: Slows how quickly the stomach empties. Can delay or change the onset of a dose taken by mouth and add to nausea. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

XULTOPHY 100/3.6 (insulin degludec and liraglutide) injection (Novo Nordisk; BLA208583) · FDA label (DailyMed) — revised 2025-10-14 | Hypoglycemia risk: "Hypoglycemia is the most common adverse reaction of insulin containing products" | Slows gastric emptying: "XULTOPHY 100/3.6 delays gastric emptying" | Withdrawal or rebound if stopped abruptly: 5.4 "Changes in an insulin regimen ... may affect glycemic control and predispose to hypoglycemia ... or hyperglycemia." | Dehydration or electrolyte risk: "gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea" | Raises blood pressure or heart rate: "Mean increases from baseline in heart rate of 2 to 3 beats per minute" | "The half-life of insulin degludec is approximately 25 hours and the half-life of liraglutide is approximately 13 hours."
TRESIBA (insulin degludec) injection (Novo Nordisk) · FDA label (DailyMed) — revised 2024-02-22 | "The glucose lowering effect of TRESIBA lasted at least 42 hours after the last of 8 once-daily injections."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →